medigraphic.com
ISSN 1561-3038 (Print)

2022, Number 3

<< Back Next >>

Rev Cubana Med Gen Integr 2022; 38 (3)

A test for early diagnosis of premalignant colonic lesions

Castellanos GM, Piñol JFN, Maceira GL

Language: Spanish
References: 27
Page:
PDF size: 483.34 Kb.


ABSTRACT

Introduction: In Cuba, colorectal cancer accounts for the third cause of death by malignant tumors, while it is a worldwide health problem, currently preventable by performing tests for the detection of premalignant lesions.
Objective: To evaluate the presumptive value of colonic premalignant lesions in patients with fecal occult blood.
Methods: An observational, descriptive and cross-sectional study was carried out in patients with fecal occult blood, who received attention in the gastroenterology service of Diez de Octubre Surgical Clinical Teaching Hospital and underwent colonoscopy, in the period from January 2016 to January 2017. To evaluate the variables, the percentage was used as a mathematical measure and the results were shown in tables.
Results: At the end of the study, a predominance of the female sex was observed. Screening, change of bowel habit and chronic diarrhea were the most frequent indications of fecal occult blood. Polyps and malignant lesions were the most frequent colonoscopic diagnoses. Malignant-appearing lesions were mostly located in the left colon. The most frequent histological diagnosis was made up of adenomas and adenocarcinomas.
Conclusions: The fecal occult blood test is a predictive method for the detection of premalignant and malignant lesions of the colon in patients who receive attention at the first level of care.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al1. . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. DOI: https://doi.org/10.1002/ijc.292101.

  2. Siegel RL, Miller KD, Fedewa SA, Miller DK, Ahnen DJ, Meester RG, et al2. . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177-193. DOI: https://doi.org/10.3322/caac.213952.

  3. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008 [acceso: 27/12/2020];67(3):253-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/18452640/ 3.

  4. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019 [acceso: 27/12/2020];394(10207):1467-80. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31631858/ 4. .

  5. Ministerio de Salud Pública (MINSAP), Dirección de Registros Médicos y Estadísticas de Salud (DNE) . Anuario estadístico de salud 2016. La Habana, Cuba: MINSAP; 2017 [acceso: 27/12/2020]. Disponible en: Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf 5.

  6. Mattiuzzi C, Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health. 2019 [acceso: 27/12/2020];9(4):217-22. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31854162/ 6. .

  7. Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu XC, Karlitz JJ. Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age. JAMA Netw Open. 2020 [acceso: 27/12/2020];3(1):e1920407. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32003823/ 7. .

  8. Ministry of Public Health (CU). Programa Integral para Control del Cáncer en Cuba. Estrategia Nacional para el Control del Cáncer. Havana: Ministry of Public Health (CU); 2012 [acceso: 13/12/2016]. Disponible en:Disponible en:http://www.paho.org/cub/index.php%3Foption%3Dcom_docman%26task%3Ddoc_download%26gid%3D378%26Itemid3D&sa=U&ei=3d6pU5a5KIilyASy74GoBA&ved=0CAYQFjAA&client=internal-uds-cse&usg=AFQjCNGbj82tkF2Qv8VdxYtRr-UC5j1XcQ 8.

  9. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al9. . Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019 [acceso: 27/12/2020];69(3):184-210. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30875085/ 9. .

  10. Hano García OM, Wood Rodríguez L, Villa Jiménez OM. Caracterización clínico-epidemiológica y endoscópica en pacientes con cáncer colorrectal. Rev Cubana Med. 2010 [acceso: 27/12/2020];49:7-16. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232010000100002&nrm=iso 10. .

  11. Lightdale CJ. Colonoscopic Polypectomy: Improved and New Methods. Gastrointest Endosc Clin N Am. 2019 [acceso: 27/12/2020];29(4):xiii-xiv. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31445694/ 11. .

  12. Hano García OM, Castellanos Gutiérrez M, Calzadilla Bertot L, Villa Jiménez OM. Validación de técnica inmunoquímica para detección de sangre oculta en heces. Rev Cubana Invest Bioméd. 2014 [acceso: 27/12/2020];33:19-33. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002014000100003&nrm=iso 12. .

  13. Geneve N, Kairys D, Bean B, Provost T, Mathew R, Taheri N. Colorectal Cancer Screening. Prim Care. 2019 [consultado 27 Dec 2020];46(1):135-48. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30704654/ 13. .

  14. Amitay EL, Gies A, Weigl K, Brenner H. Fecal Immunochemical Tests for Colorectal Cancer Screening: Is Fecal Sampling from Multiple Sites Necessary? Cancers (Basel). 2019 [acceso: 27/12/2020];11(3). Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30901946/ 14. .

  15. Herrera R, Lorenzo A, Vivar Reyes JR, Benítez Gordillo D, Gato Orozco E, López Brauet L, et al15. . SUMASOHF para el diagnóstico de sangre oculta: evaluación analítica desarrollada en el Centro de Inmunoensayo. 2012 [acceso: 27/12/2020]. Disponible en: Disponible en: http://www.convencionsalud2012.sld.cu/index.php/convencionsalud/2012/paper/viewPaper/1684 15.

  16. OMS. Detección temprana. Control del cáncer. Aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. 2007 [acceso: 17/12/2016]. Disponible en: Disponible en: http://www.who.int/cancer/publications/cancer_control_planning/es/ 16.

  17. World Medical Association (WMA) Declaration of Helsinki - Ethical principles for medical research involving human subjects. s/f [actualizado: 09/07/2018; acceso: 10/09/2021]. Disponible en: Disponible en: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/# 17.

  18. Benito L, Travier N, Binefa G, Vidal C, Espinosa J, Milà N, et al18. . Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program. Cancer Prev Res (Phila). 2019 [acceso: 27/12/2020];12(5):327-34. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30890542/ 18. .

  19. Borges LV, Mattar R, Silva J, Silva A, Carrilho FJ, Hashimoto CL. Fecal occult blood: a comparison of chemical and immunochemical tests. Arq Gastroenterol. 2018 [acceso: 27/12/2020];55(2):128-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30043860/ 19. .

  20. Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ, Amador-Romero FJ. Guía de práctica clínica. Diagnóstico y prevención del cáncer colorrectal. Actualización 2018. Gastroenterol Hepatol. 2018 [acceso: 27/12/2020];41(9):585-96. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/SO210570518302383/.

  21. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med. 2019 [acceso: 27/12/2020];7(21):609. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32047770/ 21. .

  22. Teng A, Nelson DW, Dehal A, Chang SC, Fischer T, Steele SR, et al22. . Colon cancer as a subsequent malignant neoplasm in young adults. Cancer Prev Res (Phila). 2019 [acceso: 27/12/2020];125(21):3749-54. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31290995/ 22. .

  23. Stoffel EM, Murphy CC. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. 2020 [acceso: 27/12/2020];158(2):341-53. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31394082/ 23. .

  24. Portillo Villares I. Lesiones detectadas en seis programas poblacionales de cribado de cáncer colorrectal en España. Proyecto CRIBEA. Rev Esp Salud Púb. 2017 [acceso: 27/12/2020];91(20). Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1135-57272017000100404 24.

  25. Patel AV, Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al25. . American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. Med Sci Sports Exerc. 2019 [acceso: 27/12/2020];51(11):2391-402. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31626056/ 25. .

  26. Kivés Z, Kovács A, Budai A, Döbrõssy L, Vajda R, Endrei D, et al26. . Quality and performance indicators of colorectal cancer screening pilot program in Csongrád County, Hungary. Magy Onkol. 2019 [acceso: 27/12/2020];63(2):125-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31225536/ 26. .

  27. Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, et al27. . Clinicopathological and molecular differences in colorectal cancer according to location. Int J Biol Markers. 2019 [acceso: 27/12/2020];34(1):47-53. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30854932/ 27.




2020     |     www.medigraphic.com